How does T-cell activation evolve following acute COVID-19 infection in patients with long-haul respiratory symptoms?

How do comorbid asthma, COPD, and ACO affect COVID-19 outcomes?

A recent survey of patients with aspirin-exacerbated respiratory disease identified trends in patients’ medication use and treatment experience.

What is the comparative effectiveness of biologics for treating eosinophilic asthma?

How have social distancing and other interventions to prevent the spread of COVID-19 affected pediatric asthma exacerbations?

How does a short-term halt in peanut oral immunotherapy or a reduced dosing frequency affect children who have already received a year of peanut OIT?

Can individuals who are antibody deficient produce SARS-CoV-2-specific CD4+ and CD8+ T cell responses to vaccination or infection?

An analysis of phase 3 NAVIGATOR trial data assessed the effect of tezepelumab on the percentage of asthma symptomatic days in adults and adolescents.

How does consumption of processed food by children with atopy and asthma affect the gut microbiota and disease severity?

Is peanut oral immunotherapy well-tolerated by children in the real world, and does tolerance vary by age or by peanut protein dosage?

Is omalizumab beneficial for children with asthma whose pretreatment serum IgE levels are above the drug manufacturer’s age-approved therapeutic range?

Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?

Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.

The VOYAGE trial assessed the effect of dupilumab on asthma control in children with type 2 inflammatory asthma phenotype.

Among children with peanut sensitization, is comorbid asthma associated with a higher rate of asthma exacerbations and symptoms?

Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?

APeX -2 trial findings presented at AAAAI 2022 examine the efficacy of berotralstat, in varying doses, as an oral prophylactic for reducing HAE attacks.

Does dupilumab reduce the need for systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma?

Is COVID-19 a serious concern for people with asthma? Study results presented at AAAAI 2022 show that this answer is not clear cut.

A post-hoc analysis of the LAVOLTA I and II trials assessed the effect of lebrikizumab on asthma exacerbations according to patients’ FeNO and eosinophil levels.

Research presented at AAAAI 2022 examined clinical features and cough reductions in patients with refractory vs unexplained chronic cough in phase 3 gefapixant trials.

To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?

The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.

Do immunocompromised individuals produce antibodies after receipt of an RNA-based COVID-19 vaccination?